

Section 2: References

1. *Chronic Diseases and Health Promotion*. World Health Organization Department of Chronic Diseases and Health Promotion, 2008 (<http://www.who.int/chp/en/>, accessed 18 March 2008).
2. Ezzati M et al. Selected major risk factors and global and regional burden of disease. *Lancet*, 2002, 360(9343):1347-1360.
3. World Health Organization. *Preventing chronic diseases: A vital investment*. Geneva, Switzerland, World Health Organization, 2005.
4. *The global burden of disease. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020*. Cambridge, MA, U.S.A., Harvard University Press, 1996.
5. World Health Organization. *World Health Report 2002: Reducing risks, promoting healthy life*. Geneva, Switzerland, World Health Organization, 2002.
6. Armstrong T, Bonita R. Capacity building for an integrated noncommunicable disease risk factor surveillance system in developing countries. *Ethnicity and Disease*, 2003, 13(2 Suppl 2):S13-S18.
7. Guindon G, Boisclair D. *Past, current and future trends in tobacco use*. Washington D.C., U.S., The World Bank, 2003.
8. WHO Tobacco Free Initiative. *Building blocks for tobacco control: a handbook*. Geneva, Switzerland, World Health Organization, 2004.
9. Lightwood J et al. Estimating costs of tobacco use. In: Jha P, Chaloupka F, eds. *Tobacco Control in Developing Countries*. New York, United States, Oxford University Press, 2000:63-103.
10. *CIA World Fact Book*. CIA, 2008 (<https://www.cia.gov/library/publications/the-world-factbook/>, accessed 10 January 2008).
11. Karki YB, Pant KD, Rande BR. A study on the Economics of Tobacco in Nepal. Health, Nutrition and Population (HNP) Discussion Paper. Washington D.C., U.S.A., World Bank, 2003.
12. Sesma-Vazquez S et al. Trends of tobacco demand in Mexico: 1992-1998. *Salud Publica de Mexico*, 2002, 44(Suppl 1):S82-S92.
13. World Health Organization. *Tobacco and poverty: A vicious circle*. Geneva, Switzerland, World Health Organization, 2004.

14. He J et al. Passive smoking and the risk of coronary heart disease--a meta-analysis of epidemiologic studies. *New England Journal of Medicine*, 1999, 340(12):920-926.
15. National Cancer Institute. *Health effects of exposure to environmental tobacco smoke*. National Cancer Institute, 1999.
16. The World Bank. *Curbing the epidemic. Governments and the economics of tobacco control*. Washington D.C., U.S.A., The World Bank, 1999.
17. World Health Organization. *Global Status Report on Alcohol*. Geneva, Switzerland, World Health Organization, 2004.
18. Rehm J et al. Alcohol use. In: *Global and Regional Burden of Diseases Attributable to Selected Major Risk Factors*. Geneva, Switzerland, World Health Organization, 2004:959-1108.
19. Friedman HS. Cardiovascular effects of alcohol. In: Galanter M., eds. *Recent developments in alcoholism. Vol.14: The consequences of alcoholism. Medical, Neuropsychiatric, Economic, Cross-cultural*. New York, U.S., Plenum Press, 1998:135-166.
20. Klatsky AL. Cardiovascular effects of alcohol. *Scientific American Science and Medicine*, 1995, 2:28-37.
21. National Institute on Alcohol Abuse and Alcoholism. *Ninth special report to the US Congress on alcohol and health*. Bethesda, MD, U.S.A., U.S. Department of Health and Human Services, Public Health Service, National Institute of Health, National Institute on Alcohol Abuse and Alcoholism, 1997.
22. Puddey IB et al. Influence of pattern of drinking on cardiovascular disease and cardiovascular risk factors--a review. *Addiction*, 1999, 94(5):649-663.
23. Rosenqvist M. Alcohol and cardiac arrhythmias. *Alcoholism: Clinical and Experimental Research*, 1998, 22(7 Suppl):318S-322S.
24. Wingo PA et al. Alcohol consumption and the risk of fatal breast cancer in a prospective cohort of United States Women. *American Journal of Epidemiology*, 1997, 145(Suppl):S28.
25. Berger K et al. Light-to-moderate alcohol consumption and risk of stroke among U.S. male physicians. *New England Journal of Medicine*, 1999, 341(21):1557-1564.
26. Jackson R. Cardiovascular disease and alcohol consumption: evidence of benefits from epidemiological studies. *Contemporary Drug Problems*, 1994, 21(1):5-24.

27. Ridolfo B, Stevenson CE. *The quantification of drug-caused mortality and morbidity in Australia 1998*. Canberra, Australia, Australian Institute of Health and Welfare, 2001.
28. Sacco RL et al. The protective effect of moderate alcohol consumption on ischemic stroke. *Journal of the American Medical Association*, 1999, 281(1):53-60.
29. You RX et al. Risk factors for stroke due to cerebral infarction in young adults. *Stroke*, 1997, 28(10):1913-1918.
30. Abel EL. Maternal alcohol consumption and spontaneous abortion. *Alcohol and Alcoholism*, 1997, 32(3):211-219.
31. Alvear J, Andreani S, Cortes F. [Fetal alcohol syndrome and fetal alcohol effects: importance of early diagnosis and nutritional treatment]. *Revista médica de Chile*, 1998, 126(4):407-412.
32. Bradley KA et al. Medical risks for women who drink alcohol. *Journal of General Internal Medicine*, 1998, 13(9):627-639.
33. Church MW et al. Hearing, language, speech, vestibular, and dentofacial disorders in fetal alcohol syndrome. *Alcoholism: Clinical and Experimental Research*, 1997, 21(2):227-237.
34. Faden VB, Graubard BI, Dufour M. The relationship of drinking and birth outcome in a US national sample of expectant mothers. *Paediatric and Perinatal Epidemiology*, 1997, 11(2):167-180.
35. Habbick BF et al. Mortality in foetal alcohol syndrome. *Canadian Journal of Public Health*, 1997, 88(3):181-183.
36. Larkby C, Day N. The effects of prenatal alcohol exposure. *Alcohol Research & Health*, 1997, 21(3):192-198.
37. Larroque B, Kaminski M. Alcohol consumption during pregnancy and infant birth weight. *Annals of Epidemiology*, 1996, 6(2):169-170.
38. Mattson SN et al. Heavy prenatal alcohol exposure with or without physical features of fetal alcohol syndrome leads to IQ deficits. *Journal of Pediatrics*, 1997, 131(5):718-721.
39. Passaro KT et al. The effect of maternal drinking before conception and in early pregnancy on infant birthweight. The ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. *Epidemiology*, 1996, 7(4):377-383.

40. Passaro KT, Little RE. Childbearing and alcohol use. In: Wilsnack RW, Wilsnack SC, eds. *Gender and Alcohol: Individual and Social Perspectives*. New Brunswick, NJ, U.S.A., Rutgers Center of Alcohol Studies, 1997:90-113.
41. Polygenis D et al. Moderate alcohol consumption during pregnancy and the incidence of fetal malformations: a meta-analysis. *Neurotoxicology and Teratology*, 1998, 20(1):61-67.
42. Roebuck TM, Mattson SN, Riley EP. A review of the neuroanatomical findings in children with fetal alcohol syndrome or prenatal exposure to alcohol. *Alcoholism: Clinical and Experimental Research*, 1998, 22(2):339-344.
43. Suh I et al. Alcohol use and mortality from coronary heart disease: the role of high-density lipoprotein cholesterol. The Multiple Risk Factor Intervention Trial Research Group. *Annals of Internal Medicine*, 1992, 116(11):881-887.
44. Windham GC et al. The association of moderate maternal and paternal alcohol consumption with birthweight and gestational age. *Epidemiology*, 1995, 6(6):591-597.
45. Windham GC et al. Moderate maternal alcohol consumption and risk of spontaneous abortion. *Epidemiology*, 1997, 8(5):509-514.
46. Joint WHO/FAO Expert Consultation on diet nutrition and the prevention of chronic diseases. *Diet, nutrition and the prevention of chronic diseases: report of a joint WHO/FAO expert consultation*. Geneva, Switzerland, World Health Organization, 2003.
47. Palli D. Epidemiology of gastric cancer: an evaluation of available evidence. *Journal of Gastroenterology*, 2000, 35 Suppl 12:84-89.
48. Meyer KA et al. Dietary fat and incidence of type 2 diabetes in older Iowa women. *Diabetes Care*, 2001, 24(9):1528-1535.
49. Salmeron J et al. Dietary fat intake and risk of type 2 diabetes in women. *American Journal of Clinical Nutrition*, 2001, 73(6):1019-1026.
50. Hu FB et al. Dietary fat intake and the risk of coronary heart disease in women. *New England Journal of Medicine*, 1997, 337(21):1491-1499.
51. Katan MB. Trans fatty acids and plasma lipoproteins. *Nutrition Reviews*, 2000, 58(6):188-191.
52. Vuori I. Physical inactivity as a disease risk and health benefits of increased physical activity. In: Oja P, Borms J, eds. *Perspectives-The multidisciplinary series of physical education and sport science: Health enhancing physical activity* 2004:29-73.

53. Bull F et al. Physical inactivity. In: Ezzati M et al., eds. *Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors*. Geneva, Switzerland, World Health Organization, 2004:729-881.
54. Elwood PC et al. Smoking, drinking, and other life style factors and cognitive function in men in the Caerphilly cohort. *Journal of Epidemiology and Community Health*, 1999, 53(1):9-14.
55. Mutrie N. The relationship between physical activity and clinically defined depression. In: Biddle SJH, Fox KR, Boutcher SH, eds. *Physical activity and clinically defined depression*. London, United Kingdom, Routledge, 2000:46-62.
56. Stewart R et al. Vascular risk and cognitive impairment in an older, British, African-Caribbean population. *Journal of the American Geriatrics Society*, 2001, 49(3):263-269.
57. World Health Organization. *Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series 894*. Geneva, Switzerland, World Health Organization, 2000.
58. Boyko EJ et al. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. *Diabetes Care*, 2000, 23(4):465-471.
59. Chan JM et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. *Diabetes Care*, 1994, 17(9):961-969.
60. Colditz GA et al. Weight as a risk factor for clinical diabetes in women. *American Journal of Epidemiology*, 1990, 132(3):501-513.
61. Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. *British Medical Journal*, 2001, 322(7288):716-720.
62. Despres JP. Health consequences of visceral obesity. *Annals of Medicine*, 2001, 33(8):534-541.
63. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *Journal of Hypertension*, 2003, 21(11):1983-1992.
64. Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *Journal of the American Medical Association*, 2003, 289(19):2560-2572.

65. Williams B et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. *British Medical Journal*, 2004, 328(7440):634-640.
66. Wild S et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care*, 2004, 27(5):1047-1053.
67. Roglic G et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. *Diabetes Care*, 2005, 28(9):2130-2135.
68. Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. *Diabetes Care*, 2000, 23(10):1563-1580.
69. Morrish NJ et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. *Diabetologia*, 2001, 44 Suppl 2:S14-S21.
70. Bell DS. Stroke in the diabetic patient. *Diabetes Care*, 1994, 17(3):213-219.
71. American Diabetes Association. Diabetic Nephropathy. *Diabetes Care*, 2002, 25(Suppl):S85-S89.
72. Siitonen OI et al. Lower-extremity amputations in diabetic and nondiabetic patients. A population-based study in eastern Finland. *Diabetes Care*, 1993, 16(1):16-20.
73. From the Centers for Disease Control and Prevention. Blindness caused by diabetes--Massachusetts, 1987-1994. *Journal of the American Medical Association*, 1996, 276(23):1865-1866.
74. Kuzuya T et al. Prevalence of chronic complications in Japanese diabetic patients. *Diabetes Research and Clinical Practice*, 1994, 24 Suppl:S159-S164.
75. Economic consequences of diabetes mellitus in the U.S. in 1997. American Diabetes Association. *Diabetes Care*, 1998, 21(2):296-309.
76. Bjork S. The cost of diabetes and diabetes care. *Diabetes Research and Clinical Practice*, 2001, 54 Suppl 1:S13-S18.
77. Harris MI et al. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. *Diabetes Care*, 1992, 15(7):815-819.
78. Thompson TJ et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. *Diabetic Medicine*, 1996, 13(4):337-340.
79. Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *New England Journal of Medicine*, 2002, 346(6):393-403.

80. Pan XR et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care*, 1997, 20(4):537-544.
81. Tuomilehto J et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *New England Journal of Medicine*, 2001, 344(18):1343-1350.
82. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? *British Medical Journal*, 1994, 308(6925):367-372.
83. Bennett K et al. Explaining the recent decrease in coronary heart disease mortality rates in Ireland, 1985-2000. *Journal of Epidemiology and Community Health*, 2006, 60(4):322-327.
84. Franceschini G. Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. *American Journal of Cardiology*, 2001, 88(12A):9N-13N.
85. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. *American Journal of Cardiology*, 2000, 86(9):943-949.
86. *Reflotron Plus Detailed Information*. Diavant, 2008 (<http://www.diavant.com/diavant/CMSFront.html?pgid=3,1,9,1>, accessed 18 March 2008).
87. *Accutrend Plus Detailed Information*. Diavant, 2008 (<http://www.diavant.com/diavant/CMSFront.html;jsessionid=0A6DF6CE1F1F5824F60726A97C1AA197?pgid=3,1,10047,1>, accessed 18 March 2008).
88. *HemoCue 201 DM Systems*. HemoCue, 2008 (<http://www.hemocue.com/index.php?page=13177>, accessed 18 March 2008).
89. *Accu-Chek Blood Glucose Monitoring Systems*. Roche, 2008 (<http://www.accu-chek.com/index.html>, accessed 18 March 2008).
90. *Cholestech LDX - System Overview*. Cholestech, 2008 (http://www.cholesteck.com/products/ldx_overview.htm, accessed 18 March 2008).
91. Kish L. *Survey Sampling*. New York, NY, USA, Wiley-Interscience, 1995.
92. Kish L. A Procedure for Objective Respondent Selection within the Household. *Journal of the American Statistical Association*, 1949, 44(247):380-387.

93. Lauritsen JM, Bruus M, Myatt M. EpiData - An extended tool for validated data entry and documentation of data. Version 3.1. 2001. Odense, Denmark, The EpiData Association.
94. Dean AG et al. *Epi Info, a database and statistics program for public health professionals*. Atlanta, Georgia, U.S.A., Centers for Disease Control and Prevention, 2002.
95. World Health Organization. *Guidelines for Controlling and Monitoring the Tobacco Epidemic*. 1998. Geneva, Switzerland, World Health Organization.
96. Last JM. *A dictionary of epidemiology*. New York, U.S.A., Oxford University Press, 2001.
97. *World Health Organization Tobacco Free Initiative*. World Health Organization, 2008 (<http://www.who.int/tobacco/en/>, accessed 18 March 2008).
98. World Health Organization. *The Tobacco Atlas*. Geneva, Switzerland, World Health Organization, 2002.
99. Rehm J et al. The global distribution of average volume of alcohol consumption and patterns of drinking. *European Addiction Research*, 2003, 9(4):147-156.
100. World Health Organization. *International Guide for Monitoring Alcohol Consumption and Related Harm*. Geneva, Switzerland, World Health Organization, 2000.
101. Haskell WL et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. *Circulation*, 2007, 116(9):1081-1093.
102. *IPAQ - International Physical Activity Questionnaire*. Karolinska Institutet, 2008 (<http://www.ipaq.ki.se/>, accessed 9 January 2008).
103. *Global Strategy on Diet, Physical Activity and Health*. World Health Organization Department of Chronic Diseases and Health Promotion, 2008 (<http://www.who.int/dietphysicalactivity/en/>, accessed 18 March 2008).
104. World Health Organization. *Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854*. Geneva, Switzerland, World Health Organization, 1995.
105. *Global Database on Body Mass Index*. World Health Organization, 2008 (http://www.who.int/bmi/index.jsp?introPage=intro_3.html, accessed 19 February 2008).

106. *Obesity and Overweight: Defining Overweight and Obesity*. Centers for Disease Control and Prevention (CDC), Division of Nutrition, Physical Activity and Obesity (DNPAO), 2008 (<http://www.cdc.gov/nccdphp/dnpa/obesity/defining.htm>, accessed 18 March 2008).
107. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet*, 2004, 363(9403):157-163.
108. Guidelines Subcommittee of the World Health Organization - International Society of Hypertension (WHO-ISH). 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. *Journal of Hypertension*, 1999, 17:151-183.
109. World Health Organization Department of Noncommunicable Disease Surveillance. *Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus*. Geneva, Switzerland, World Health Organization, 1999.
110. World Health Organization. *Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk*. Geneva, Switzerland, World Health Organization, 2007.
111. World Health Organization. *Avoiding heart attacks and strokes: don't be a victim - protect yourself*. Geneva, Switzerland, World Health Organization, 2005.
112. *Cholesterol Levels*. American Heart Association, 2008 (<http://www.americanheart.org/presenter.jhtml?identifier=4500>, accessed 18 March 2008).
113. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*, 2002, 106(25):3143-3421.
114. Bonita R, Beaglehole R, Kjellström T. *Basic Epidemiology*. Geneva, Switzerland, World Health Organization, 2006.

